The FDA has eliminated Risk Evaluation and Mitigation Strategies (REMS) for six CAR T therapies targeting BCMA and CD19 antigens used in multiple myeloma and certain leukemias and lymphomas. This decision reflects extensive real-world evidence and expert experience in managing side effects like cytokine release syndrome and neurotoxicity, aiming to streamline access and expand community center administration. Cell and gene therapy leaders and analysts have praised the agency's move to reduce regulatory burden and hasten patient access to potentially curative therapies, while also shortening patient post-treatment monitoring requirements.